U.S. Markets close in 5 hrs 30 mins
  • S&P 500

    4,558.85
    +9.07 (+0.20%)
     
  • Dow 30

    35,748.91
    +145.83 (+0.41%)
     
  • Nasdaq

    15,192.21
    -23.49 (-0.15%)
     
  • Russell 2000

    2,295.90
    -0.28 (-0.01%)
     
  • Gold

    1,813.30
    +31.40 (+1.76%)
     
  • EUR/USD

    1.1654
    +0.0023 (+0.1981%)
     
  • 10-Yr Bond

    1.6640
    -0.0120 (-0.72%)
     
  • Vix

    15.04
    +0.03 (+0.20%)
     
  • GBP/USD

    1.3789
    -0.0006 (-0.0455%)
     
  • USD/JPY

    113.6410
    -0.3470 (-0.3044%)
     
  • BTC-USD

    61,804.26
    -1,862.18 (-2.92%)
     
  • CMC Crypto 200

    1,467.26
    -35.78 (-2.38%)
     
  • FTSE 100

    7,232.91
    +42.61 (+0.59%)
     
  • Nikkei 225

    28,804.85
    +96.27 (+0.34%)
     

Why Iovance Is Up Nearly 11% Today

·2 min read
Why Iovance Is Up Nearly 11% Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of biopharma company Iovance (NASDAQ: IOVA) are poised to end Wednesday's trading session almost 11% higher than Tuesday's close, following an encouraging observation from investment analytics outfit Truist. Namely, the odds of an approval of one of its drug prospects seemingly improved after a rival drug developer was granted permission to expand its trials of a similar therapy. On Monday, Instil Bio (NASDAQ: TIL) announced the Food and Drug Administration had cleared the company's request to widen the scope of its current phase 2 trial of ITIL-168.